Spark Therapeutics (NASDAQ:ONCE) Downgraded to Hold at ValuEngine

Spark Therapeutics (NASDAQ:ONCE) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Tuesday, ValuEngine reports.

A number of other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Mizuho reissued a “hold” rating and set a $114.50 target price on shares of Spark Therapeutics in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating and twelve have issued a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $106.00.

Spark Therapeutics stock opened at $111.30 on Tuesday. The company has a quick ratio of 4.35, a current ratio of 4.67 and a debt-to-equity ratio of 0.35. The firm has a 50-day moving average price of $108.19 and a two-hundred day moving average price of $103.26. The firm has a market capitalization of $4.28 billion, a price-to-earnings ratio of -52.75 and a beta of 2.05. Spark Therapeutics has a 52-week low of $34.53 and a 52-week high of $114.20.

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its position in shares of Spark Therapeutics by 4,568.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 887 shares of the biotechnology company’s stock worth $86,000 after buying an additional 868 shares in the last quarter. CSat Investment Advisory L.P. bought a new stake in shares of Spark Therapeutics during the 2nd quarter worth about $113,000. Nisa Investment Advisors LLC raised its position in shares of Spark Therapeutics by 651.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,010 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Spark Therapeutics during the 2nd quarter worth about $202,000. Finally, Ancora Advisors LLC bought a new stake in shares of Spark Therapeutics during the 2nd quarter worth about $205,000. Institutional investors own 88.36% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Featured Article: Holder of Record

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.